Estrogen receptor genotypes and haplotypes associated with breast cancer risk

Cancer Research

Volumn 64, Issue 24, 2004, Pages 8891-8900

  Gold, Bert ^a   Kalush, Francis ^b,c   Bergeron, Julie ^d   Scott, Kevin ^d   Mitra, Nandita ^e   Wilson, Kelly ^b,c   Ellis, Nathan ^e   Huang, Helen ^e   Chen, Michael ^d   Lippert, Ross ^f,g   Halldorsson, Bjarni V ^f   Woodworth, Beth ^a   White, Thomas ^b,c   Clark, Andrew G ^b,c   Parl, Fritz F ^h   Broder, Samuel ^b,c   Dean, Michael ^a   Offit, Kenneth ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Celera Genomics   (United States)

^c CELERA   (United States)

^d SAIC FREDERICK INC   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Applied Biosystems   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

BASE SEQUENCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHNIC GROUPS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS;

EID: 10844265490     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1256     Document Type: Article

References (59)

1. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279:915-21.
2. Vehmanen P, Friedman LS, Eerola H, et al. A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet 1997;60:1050-8.
3. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
4. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
5. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 1983;309:1343-7.
6. Parl FF. Estrogens, estrogen receptor and breast cancer. Amsterdam: IOS Press/Ohmsha; 2000.
7. de Jong MM, Nolte IM, te Meerman GJ, et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 2002;39:225-42.
8. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-13.
9. Hanstein B, Djahansouzi S, Dall P, Beckmann MW, Bender HG. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur J Endocrinol 2004;150:243-55.
10. Tempfer CB, Schneeberger C, Huber JC. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics 2004;5:57-65.
11. Lymberis SC, Parhar PK, Katsoulakis E, Formenti SC. Pharmacogenomics and breast cancer. Pharmacogenomics 2004;5:31-55.
12. Bland KI, Copeland EM. The breast: comprehensive management of benign and malignant disorders. 3rd ed. St. Louis: Saunders; 2004.
13. Clark VJ, Metheny N, Dean M, Peterson RJ. Statistical estimation and pedigree analysis of CCR2-CCR5 haplotypes. Hum Genet 2001;108:484-93.
14. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
15. Fallin D, Cohen A, Essioux L, et al. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res 2001;11:143-51.
16. Long JC. Multiple locus haplotype analysis (MLOCUS, OBSHAP, PAIRWISE), Software and documentation distributed by the author. Section on population genetics and linkage, 2.0 ed. Bethesda, MD: Laboratory of Neurogenetics, NIAAA, National Institutes of Health; 1999.
17. Clark AG. Inference of haplotypes from PCR-amplified samples of diploid populations. Mol Biol Evol 1990;7:111-22.
18. Fullerton SM, Clark AG, Weiss KM, et al. Sequence polymorphism at the human apolipoprotein All gene (APOA2): unexpected deficit of variation in an African-American sample. Hum Genet 2002;111:75-87.
19. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
20. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001;29:233-7.
21. Bafna VH, BV, Schwartz RS, Clark AG, Istrail S. Haplotypes and informative SNP selection algorithms: don't block out information. Proceedings of the Seventh Annual International Conference on Computational Molecular Biology (RECOMB) 2003:19-27.
22. Fallin D. Haplotype-based approaches to genetic case-control studies [Ph.D. Dissertation]. Cleveland, Ohio: Case Western Reserve university; 2001.
23. Mitchell MK, Gregersen PK, Johnson S, Parsons R, Vlahov D. The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health 2004;81:301-10.
24. Roodi N, Bailey LR, Kao WY, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst (Bethesda) 1995;87:446-51.
25. Zuppan P, Hall JM, Lee MK, Ponglikitmongkol M, King MC. Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease. Am J Hum Genet 1991;48:1065-8.
26. Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 1994;94:665-70.
27. Iwase H, Greenman JM, Barnes DM, Hodgson S, Bobrow L, Mathew CG. Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. Cancer Lett 1996;108:179-84.
28. Wang M, Dotzlaw H, Fuqua SA, Murphy LC. A point mutation in the human estrogen receptor gene is associated with the expression of an abnormal estrogen receptor mRNA containing a 69 novel nucleotide insertion. Breast Cancer Res. Treat 1997;44:145-51.
29. Cai Q, Gao YT, Wen W, et al. Association of breast cancer risk with a GT dinucleotide repeat polymorphism upstream of the estrogen receptor-alpha gene. Cancer Res 2003;63:5727-30.
30. Cai Q, Shu XO, Jin F, et al. Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomark Prev 2003;12:853-9.
31. Southey MC, Batten LE, McCredie MR, et al. Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. J Natl Cancer Inst (Bethesda) 1998;90:532-6.
32. Schubert EL, Lee MK, Newman B, King MC. Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Mol Biol 1999;71:21-7.
33. Kang HJ, Kim SW, Kim HJ, et al. Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk. Cancer Lett 2002;178:175-80.
34. Herrington DM, Howard TD, Brosnihan KB, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002;105:1879-82.
35. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 2004;291:2969-77.
36. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-30.
37. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53.
38. Zou A, Marschke KB, Arnold KE, et al. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol Endocrinol 1999;13:418-30.
39. Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 2001;20:8109-15.
40. Poola I, Abraham J, Liu A. Estrogen receptor beta splice variant mRNAs are differentially altered during breast carcinogenesis. J Steroid Biochem Mol Biol 2002;82:169-79.
41. Poola I, Clarke R, DeWitty R, Leffall LD. Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women. Cancer (Phila) 2002;94:615-23.
42. Saji S, Omoto Y, Shimizu C, et al. Clinical impact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer 2002;9:303-7.
43. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) betal and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 2003;22:5011-20.
44. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JA. Update on estrogen signaling. FEBS Lett 2003;546:17-24.
45. Forsti A, Zhao C, Israelsson E, Dahlman-Wright K, Gustafsson JA, Hemminki K. Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association. Breast Cancer Res Treat 2003;79:409-13.
46. Hasegawa S, Miyoshi Y, Ikeda N, et al. Mutational analysis of estrogen receptor-beta gene in human breast cancers. Breast Cancer Res Treat 2003;78:133-4.
47. Zheng SL, Zheng W, Chang BL, et al. Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res 2003;63:7624-9.
48. Rosenkranz K, Hinney A, Ziegler A, et al. Systematic mutation screening of the estrogen receptor beta gene in probands of different weight extremes: identification of several genetic variants. J Clin Endocrinol Metab 1998;83:4524-7.
49. Sundarrajan C, Liao WX, Roy AC, Ng SC. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J Clin Endocrinol Metab 2001;86:135-9.
50. Ogawa S, Hosoi T, Shiraki M. et al. Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem Biophys Res Commun 2000;269:537-41.
51. De Vivo I, Huggins GS, Hankinson SE, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA 2002;99:12263-8.
52. Rebbeck TR, Ambrosone CB, Bell DA, et al. SNPs, haplotypes, and cancer: applications in molecular epidemiology. Cancer Epidemiol Biomark Prev 2004;13:681-7.
53. Nyholt DR. Genetic case-control association studies - correcting for multiple testing. Hum Genet 2001;109:564-7.
54. Krawczak M, Boehringer S, Epplen JT. Correcting for multiple testing in genetic association studies: the legend lives on. Hum Genet 2001;109:566-7.
55. Boehringer S, Epplen JT, Krawczak M. Genetic association studies of bronchial asthma - a need for Bonferroni correction? Hum Genet 2000;107:197.
56. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-8.
57. Bonferroni CE. Teoria statistica delle classi e calcolo delle probabilità. Pubblicazioni del R Instituto Superiore di Scienze Economiche e Commericiali di Firenze 1936;8:3-62.
58. Fallin D, Schork NJ. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 2000;67:947-59.
59. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.